Zacks Investment Research on MSN
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
Vertex Pharmaceuticals (VRTX) ended the recent trading session at $381.87, demonstrating a +1.39% change from the preceding day's closing price. The stock outpaced the S&P 500's daily loss of 0.5%. At ...
The FDA granted breakthrough therapy designation to a Vertex Pharmaceuticals kidney disease drug.
Vertex also announced enrollment completion of the IA cohort of AMPLITUDE, a global Phase 2/3 clinical trial designed to assess the impact of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback